期刊文献+

高分子聚合物逆转血浆所致肺表面活性物质失活 被引量:1

Polymers reverse inactivation of surfactant induced by plasma
原文传递
导出
摘要 目的包括血浆在内的许多物质能够抑制肺表面活性物质(PS)降低表面张力的能力,这是急性肺损伤(ALI)和急性呼吸窘迫综合征(ARDS)的重要病理改变之一。本研究的目的是探讨高分子聚合物是否可以防止或减轻血浆诱导的Ps失活。方法利用闭泡式表面张力仪分别测量葡聚糖(dextran)、聚乙二醇(PEG)和透明质酸(HA)、PS(固尔苏,curosurf)以及加入了1%~3%血浆的混合物最大表面张力(γmax)和最小表面张力(γmin),并计算它们的稳定系数(SI)。结果不同高分子聚合物、血浆及它们的混合物γmin均〉10mN/m,SI〈0.8,而curosurf(1.25mg/ml)的γmin为(1.54±0.03)mN/m,SI为1.71±0.01。Curosurf与1%、2%或3%的血浆混合后γmin分别为(19.0±0.46)mN/m、(22.9±0.42)mN/m和(22.6±1.22)mN/m,SI为0.38±0.05、0.34±0.02和0.39±0.15。 述混合物与5%PEG、5%dextran或0.25%HA混合,γmin分别降至(1.59±0.22)mN/m、(1.43±0.24)mN/m、(17.2±0.72)mN/m;(0.88±0.06)mN/m、(1.18±0.06)mN/m、(1.46±0.22)mN/m及(1.22±0.10)mN/m、(1.33±0.07)mN/m、(1.42±0.18)mN/m,与curosurf同各浓度血浆混合物比较,差异均有统计学意义(P均〈0.05)。S1分别增加到1,72±0.04、1.73±0.04、0.43±0.04;1.82±0.01、1.82±0.01、1.79±0.03及1.79±0.02、1.79±0.01、1.79±0.04,与curosurf同各浓度血浆混合物比较,差异均有统计学意义(P均〈0.05)。不同浓度的高分子聚合物显著提高了血浆存在情况下curosurf降低γmin、增加SI的能力(rPEG=-0.718,P〈0.01;rdextran=-0.682,P〈0.01;rHA=-0.889,P〈0.01)。结论高分子聚合物可以逆转血浆所致的curosurf失活,和PEG比较,dextran和HA与curosurf联合应用可以更好地对抗血浆的抑制。 Objective Objective A variety of substances including plasma have been found to affect adversely the surface tension-lowering activity of pulmonary surfactant, and this effect may be important in the pathogenesis of a number of human diseases such as acute lung injury(ALI) and acute respiratory distress syndrome( ARDS). We were aimed at exploring whether inactivation of surfactant induced by plasma could be prevented or reduced by polymers. Methods We measured the maximum (γmax) and minimum sueface tension ( γmin ) of dextran, polyethylene glycol (PEG), hyaluronan(HA), pulmonary surfactant( Curosurf), plasma and their mixtures by captive bubble surfactometer, respectively. Values of stability index(S. I. ) were also calculated. Results The γmin of different polymers, plasma and their mixtures were more than 10 mN/m and S. I. of which were less than 0.8. The γmin and S. I. of Curosurf( 1.25 mg/ ml) were (1.54± 0.03)mN/m and 1.71 ± 0.01, respectively. The rain and S. I. of Curosurf mixed with 1% ,2% or 3% plasma were( 19.0 ± 0.46) mN/m, (22.9 ± 0.42) mN/m and(22.6 ± 1.22) mN/m and 0.38 ± 0.05,0.34 ± 0.02 and0.39 ± 0.15, respectively. When mixed with 5% PEG, 5% dextran and 0.25% HA, the γmin significantly decreased to[ (1.59 ± 0.22)mN/m, (1.43 ± 0.24) mN/m, ( 17.2 ± 0.72)mN/m; (0.88 ± 0. (36)mN/m, ( 1.18 ± 0.(36)mN/m, (1.46±0.22)mN/m and (1.22 ± 0.10 )mN/m, (1.33 ± 0.07 )mN/m, (1.42 ± 0.18 )mN/m,respectively, ( P 〈 0.05 ) ,and the S. I. significantly increasedto to 1.72 ± 0. 04,1.73 ±0. 04,0.43 ±0.04;1.82±0.01 ,1.79±0.03 and 1.79±0.02,1.79±0.01,1.79±0.04 respectively, ( P 〈 0.05 ). Different concentrations of polymers significantly enhanced the ability of Curosurf in reducing the γmin and elevating S. I. in the presence of plasma. Conclusion PoIymers are capable of reversing inactivation of surfactant induced by plasma in vitro. The data suggests that dextran and HA be more effective to lower the γmin than PEG when mixed with Curosurf.
机构地区 首都儿科研究所
出处 《国际儿科学杂志》 2008年第4期298-301,共4页 International Journal of Pediatrics
基金 北京市自然科学基金资助项目(7042018)
关键词 聚合物 肺表面活性剂 血浆 最小表面张力 稳定系数 Polymers Ptdmonary Surfactants Plasma Minimum Surface Tension Stability Index
  • 相关文献

参考文献13

  • 1Lewis JF, Veldhuizen R. The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol, 2003,65 : 613-642.
  • 2邓渊,董声焕,张广安,马金贵.可控闭泡式表面张力测定仪的研制[J].中国医疗器械杂志,1994,18(2):87-89. 被引量:6
  • 3Schurch S,Bachofen H,Goerke J,et al.A captive bubble method reproduces the in situ behavior of lung surfactant monolayers. Appl Physiol, 1989,67(6) : 2389-2396.
  • 4Schurch S, Bachofen H, Goerke J, et al. Surface properties of rat pulmonary surfactant studied with the captive bubble mothed: adsorption, hysteresis, stability. Biochim Biophys Acta, 1992,1103( 1 ) : 127-136.
  • 5Taeusch HW. Treatment of acute (adult) respiratory distress syndrome: the holy grail of surfactant therapy. Biol Neonate,.2000,77 Suppl 1:2-8.
  • 6Frerking I, Gtinther A, Seeger W, et al. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med, 2001,27( 11 ) : 1699-1717.
  • 7Taeusch HW,Lu KW,Goerke J,et al.Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med, 1999,159 (5 Pt 1):1391-1395.
  • 8Kobayashi T, Ohta K, Tashiro K, et al. Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract . Appl Physiol, 1999, 86 (6) : 1778-1784.
  • 9Lu KW, Goerke J, Clements JA, et al. Hyaluronan decreases surfactant inactivation in vitro. Pediatr Res, 2005,57(2):237-241.
  • 10Sun B,Curstedt T,Lindgren G,et al .Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A. Eur Respir J, 1997,10(9) : 1967-1974.

共引文献5

同被引文献16

  • 1邓渊,董声焕,张广安,马金贵.可控闭泡式表面张力测定仪的研制[J].中国医疗器械杂志,1994,18(2):87-89. 被引量:6
  • 2甘小庄,宋国维,黄伟雄,孙丽萍,马广松,李惠.肺表面活性物质功能不良的机制探讨[J].中国危重病急救医学,1996,8(3):136-138. 被引量:3
  • 3Howell EA, Holzman I, Kleinman LC,et al. Surfactant use for premature infants with respiratory distress syndrome in three new york city hospi- tals: Discordance of practice from a community clinician consensus standard[J]. J Perinatol,2010,30(9) :590 -595.
  • 4Van Kaam AH, de Jaegere AP, Borensztajn D, et al. Surfaetant replace- ment therapy in preterm infants : A European survey [ J ]. Neonatology, 2011,100(1 ) :71 -77.
  • 5Lu KW, Perez -Gil J, Taeusch HW. Kinematic viscosity of therapeutic pulmonary surfactants with added polymers [J]. Biochim Biophys Acta, 2009,1788 (3) :632 - 637.
  • 6Zasadzinski JA, Stenger PC, Shieh f,et al. Overcoming rapid inactivation of lung surfactant:Analogies between competitive adsorption and colloid stability [J]. Biochim Biophys Acta,2010,1798 (4) : 801 - 828.
  • 7Iwanicki JL, Lu KW, Taeusch HW. Reductions of phospholipase A (2) inhibition of pulmonary surfactant with hyaluronan [ J ]. Exp Lung Res, 2010,36(3) :167 - 174.
  • 8Lopez- Rodriguez E,Echaide M,Cruz A,et al. Meconium impairs pul- monary surfactant by a combined action of cholesterol and bile acids [J]. Biophys J, 2011,100 ( 3 ) : 646 - 655.
  • 9Tashiro K,Kobayashi T, Robertson B. Dextran reduees suefb.ntant inhi- bition by meconium [ J ]. Acta Paediatr,2000,89 ( 12 ) : 1439 - 1445.
  • 10Lu KW,Taeusch HW. Combined effects of polymers and KL(4) pep- tide on surface activity of pulmonary surfactant lipids[ J ]. Biochim Bio- phys Acta,2010,1798(6) :1129 - 1134.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部